Matthew Banegas, PhD, MPH, is a health services and health disparities researcher who studies the delivery, costs and value of health care. Dr. Banegas came to the Center for Health Research in April 2015.
In his time at CHR, Dr. Banegas has developed a new breast cancer risk assessment tool specifically for Latina populations, worked directly with the delivery system to develop and evaluate a financial navigator program, and helped implement strategies for measuring and addressing patient social needs within the health care system. A large body of his work focuses on understanding patient financial and employment-related challenges to get a complete picture of the economic impacts of cancer diagnosis and treatment on patients and survivors. His work on financial hardship is included in the National Cancer Institute (NCI) Financial Toxicity and Cancer Treatment Physician Data Query (PDQ®) web resource, and the recent President’s Cancer Panel report on Promoting Value, Affordability, and Innovation in Cancer Drug Treatment. Dr. Banegas is also a Steering Committee Member of the Social Needs Network for Evaluation and Translation (SONNET), a group created to implement Kaiser Permanente's vision to address the social, economic and behavioral needs (SEBN) of our members.
Before arriving at CHR, Dr. Banegas completed his postdoctoral work in the Cancer Prevention Fellowship Program (CPFP) at the NCI in the Division of Cancer Control and Population Sciences, Health Services and Economics Branch. Since his time as a fellow he has been a member of an interagency consortium called HEROiC that aims to develop research resources and reduce the economic burden of cancer in the United States. Dr. Banegas received his MS and MPH degrees from New Mexico State University and his PhD in health services research, with a concentration on cancer prevention and control, from the University of Washington/Fred Hutchinson Cancer Research Center.
- Banegas MP, Yabroff K, O'Keefe Rosetti M, Ritzwoller DP, Fishman PA, Salloum RG, Elston Lafata J, Hornbrook MC. Medical Care Costs Associated with Cancer in Integrated Delivery Systems. Journal of National Comprehensive Cancer Network 2018 Apr;16:402-410 [PMID: 29632060]
- Banegas MP, Dickerson JF, Kent EE, de Moor JS, Virgo KS, Guy GP Jr, Ekwueme DU, Zheng Z, Nutt S, Pace L, Varga A, Waiwaiole L, Schneider J, Yabroff KR. Exploring barriers to the receipt of necessary medical care among cancer survivors under age 65 years. J Cancer Surviv 2018 Feb;12(1):28-37. [PMID: 28852970]
- Banegas MP, Guy GP, de Moor JS, Ekwueme DU, Virgo KS, Zheng J, Kent E, Nutt S, Yabroff KR. Financial Hardship among Working-age Cancer Survivors: Medical Debt and Bankruptcy. Health Affairs 2016 Jan 1;35(1):54-61. [PMID: 26733701]
- Emerson M, Banegas MP, Chawla N, Achacoso N, Alexeeff SE, Adams AS, Habel LA. Disparities in prostate, lung, breast and colorectal cancer survival and comorbidity status among urban American Indians and Alaskan Natives. Cancer Research 2017 Dec 1;77(23):6770-6776 [PMCID: PMC5728425]
- Banegas MP, John EM, Slattery ML, Gomez SL, Yu M, LaCroix AZ, Pee D, Chlebowski RT, Hines LM, Thomson CA, Gail MH. Projecting Individualized Absolute Invasive Breast Cancer Risk in U.S. Hispanic Women. Journal of the National Cancer Institute 2016 Dec 20;109(2). pii: djw215 [PMID: 28003316; PMCID: PMC5174188]
- Zheng J, Jemal A, Guy GP, Han X, Banegas MP, Li C, Ekwueme DU, Yabroff KR. Annual Medical Expenditure and Productivity Loss among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States. Journal of the National Cancer Institute 2015 Dec 24;108(5). [PMCID: PMC4849808]
- McDougall JA, Banegas MP, Wiggins C, Rajput A, Chiu VK, Flores K, Kinney A. Rural Disparities in Treatment-Related Financial Hardship and Adherence to Surveillance Colonoscopy in Diverse Colorectal Cancer Survivors. Cancer Epidemiology, Biomarkers & Prevention 2018 Mar 28. pii: cebp.1083.2017. [PMID: 29593011, Epub 2018 Mar 28]
- Zheng Z, Han X, Guy GP Jr, Davidoff AJ, Li C, Banegas MP, Ekwueme DU, Yabroff KR, Jemal A. Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States. Cancer 2017 Apr 15;123(8):1453-1463 [PMID: 28218801]